Grifulvin V: Effective Oral Antifungal for Dermatophyte Infections
Grifulvin V
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.43 | $43.00 (0%) | 🛒 Add to cart |
| 60 | $1.10 | $86.00 $66.00 (23%) | 🛒 Add to cart |
| 90 | $0.99 | $129.00 $89.00 (31%) | 🛒 Add to cart |
| 120 | $0.93 | $172.00 $112.00 (35%) | 🛒 Add to cart |
| 180 | $0.87 | $258.00 $157.00 (39%) | 🛒 Add to cart |
| 270 | $0.83 | $387.00 $225.00 (42%) | 🛒 Add to cart |
| 360 | $0.81
Best per pill | $516.00 $292.00 (43%) | 🛒 Add to cart |
Synonyms
| |||
Grifulvin V (griseofulvin microsize) represents a cornerstone in systemic antifungal therapy, specifically formulated to combat dermatophyte infections that topical agents cannot adequately address. As a microcrystalline preparation, it offers enhanced bioavailability and consistent absorption, making it a clinically validated choice for treating tinea infections affecting the skin, hair, and nails. This oral antifungal works by inhibiting fungal cell division and disrupting hyphal growth, providing a targeted mechanism that supports comprehensive eradication of susceptible organisms. Prescribed for decades with a well-established safety profile, Grifulvin V remains a trusted option in dermatological and pediatric practice when prolonged antifungal treatment is required.
Features
- Contains griseofulvin microsize 500 mg per tablet
- Oral administration with fatty meals to optimize absorption
- Fungistatic activity against Trichophyton, Microsporum, and Epidermophyton species
- Available in scored tablets for accurate dosing
- Manufactured under strict pharmaceutical compliance standards
Benefits
- Systemically treats dermatophyte infections beyond the reach of topical therapies
- Prevents further spread of infection to healthy skin and nails
- Reduces recurrence rates when used for full prescribed duration
- Suitable for pediatric and adult populations with appropriate weight-based dosing
- Supported by decades of clinical use and established treatment protocols
Common use
Grifulvin V is indicated for the treatment of ringworm (tinea corporis), athlete’s foot (tinea pedis), jock itch (tinea cruris), barber’s itch (tinea barbae), scalp ringworm (tinea capitis), and nail infections (tinea unguium) caused by susceptible dermatophyte fungi. It is particularly valuable when infections are widespread, recurrent, or involve hair follicles and nail beds where topical antifungals demonstrate limited penetration. The medication is commonly prescribed for children with tinea capitis and adults with extensive dermatophytoses requiring systemic therapy.
Dosage and direction
Dosage must be individualized based on infection severity, patient weight, and specific pathogen involved. For adults: 500 mg daily in single or divided doses; severe infections may require 1 g daily. For children: 5 mg per pound of body weight daily is generally effective, though some infections may require up to 10 mg per pound. Administration with fatty meals significantly enhances absorption. Treatment duration varies considerably—tinea corporis typically requires 2-4 weeks, while tinea unguium may necessitate several months of therapy. Continue treatment until clinical and laboratory evidence confirms eradication, typically for at least 2 weeks after symptoms subside.
Precautions
Periodic monitoring of hepatic, renal, and hematopoietic function is recommended during prolonged therapy. Use with caution in patients with porphyria, hepatic impairment, or pre-existing blood dyscrasias. Griseofulvin may decrease the efficacy of oral contraceptives; additional contraceptive methods are advised. Photosensitivity reactions may occur—advise patients to use protective measures against natural and artificial UV exposure. Alcohol consumption may precipitate tachycardia and flushing reactions. Not recommended during pregnancy or in men attempting to father children during and for six months after therapy due to potential effects on sperm production.
Contraindications
Grifulvin V is contraindicated in patients with known hypersensitivity to griseofulvin or any component of the formulation. Contraindicated in patients with porphyria or hepatocellular failure. Should not be administered to pregnant patients or those who may become pregnant during therapy due to potential teratogenic effects. Not recommended for patients with a history of blood dyscrasias. Contraindicated in patients receiving concurrent therapy with barbiturates due to decreased griseofulvin absorption.
Possible side effects
Common side effects include headache (approximately 15% of patients), gastrointestinal disturbances including nausea, vomiting, diarrhea, and epigastric distress. Less frequently reported are rash, urticaria, and angioedema. Rare but serious adverse effects include proteinuria, leukopenia, granulocytopenia, hepatitis, and peripheral neuropathy. Psychiatric disturbances including confusion and impaired coordination have been reported. Photosensitivity reactions may manifest as exaggerated sunburn or skin rash.
Drug interaction
Griseofulvin induces hepatic microsomal enzymes, potentially decreasing the efficacy of warfarin-type anticoagulants—monitor prothrombin time closely. Concurrent use with barbiturates decreases griseofulvin absorption, requiring dosage adjustment. May reduce the efficacy of oral contraceptives; recommend backup contraception. Potential interaction with cyclosporine may reduce cyclosporine levels. Concurrent alcohol use may cause disulfiram-like reactions including tachycardia and flushing.
Missed dose
If a dose is missed, administer as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Maintain regular dosing schedule to ensure consistent antifungal levels. If multiple doses are missed, contact healthcare provider for guidance on resumption of therapy.
Overdose
Symptoms of overdose may include severe nausea, vomiting, diarrhea, and central nervous system depression including dizziness, confusion, and blurred vision. No specific antidote exists; treatment should be symptomatic and supportive. Gastric lavage may be considered if ingestion occurred recently. Monitor hepatic and renal function, and provide appropriate hydration and electrolyte management. Hemodialysis is not effective for griseofulvin removal.
Storage
Store at controlled room temperature (20°-25°C or 68°-77°F) in original container. Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use after expiration date printed on packaging. Do not transfer to other containers as moisture protection may be compromised.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Grifulvin V is available by prescription only and should be used under appropriate medical supervision. Healthcare providers should review full prescribing information before administration. Individual patient response may vary, and treatment decisions should be based on clinical judgment and patient-specific factors.
Reviews
Clinical studies demonstrate mycological cure rates of 70-90% for various dermatophytoses when used as directed. Dermatologists consistently report satisfactory response in tinea capitis cases, particularly in pediatric populations. Some practitioners note the requirement for prolonged treatment duration as a limitation compared to newer antifungals, but appreciate the established safety profile and cost-effectiveness. Patient compliance sometimes challenges due to gastrointestinal side effects and need for fatty meal co-administration, though most complete therapy successfully with proper education and monitoring.